Illegal Activity
none
Blackmail
none
Date
2015-08-13
Document Type
report
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:43
Summary
Avalanche Biotechnologies reported its second quarter 2015 financial results, announcing a loss of $0.38 per share and revenue of $0.2 million. The company also announced it would not initiate Phase 2b trials for AVA-101, opting instead for further preclinical studies.
Metadata
- Subject
- Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program
- Sender
- Jeremy R. Cooke
- Recipients
- —
- Document ID
- SDNY_GM_00206441
- Date
- 2015-08-13
Relationships 2
| Entity 1 | Relationship | Entity 2 | Description |
|---|---|---|---|
| Avalanche Biotechnologies, Inc. | product | AVA-101 | Avalanche Biotechnologies is developing AVA-101 for wet AMD treatment. |
| Jeremy R. Cooke | employee | Bloomberg | Jeremy R. Cooke is an employee of Bloomberg. |
Notable Quotes 2
Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA-101 for potential treatment of wet age-related macular degeneration.
AAVL instead will run added preclinical studies to investigate optimal dose and delivery of AVA-101 and AVA-201 vs standard of care anti-VEGF protein therapy to select best gene therapy product candidate for wet AMD
Financial Information
Amounts:0.2M0.4M279.6m159.4m38c37c
Assets:
- Cash/equivalents $279.6m as of June 30 vs $159.4m at end of 2014
Media & Journalist References
- Jeremy R. Cooke (Bloomberg)
Public Knowledge
- Context
- Financial results and drug trial updates are generally of interest to the media.
- Media Worthy
- Yes
Raw Analysis JSON
click to expand
Themes
Financial transactions/money flowBusiness dealings
People 1
Organizations 2
Avalanche Biotechnologies, Inc.Bloomberg
Text Analysis
- Tone
- Informative
- Purpose
- To report Avalanche Biotechnologies' second quarter 2015 financial results and provide an update on the AVA-101 program.
- Significance
- The report details Avalanche Biotechnologies' decision to halt Phase 2b trials for AVA-101 and instead focus on preclinical studies.
File Info
- File Name
- EFTA01368503.txt
- Dataset
- dataset_10
- Type
- Text
- Model
- gemini-2.0-flash-001
- Processed
- 2026-02-07T18:43:06.212567
- DOJ Source
- View on DOJ